Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cancer Insights

- PMLiVE

Healthcare Heroes

The people behind the curtain

- PMLiVE

The Creative Floor Healthcare Awards finalists announced

McCann Health London, Havas Lynx and Concentric are among those shortlisted

Healthcare Heroes – The Passion Project by Havas Lynx

The Havas Lynx group are incredibly proud to launch ’Healthcare Heroes, the passion project.’ This campaign shares inspirational stories from doctors, nurses, patients, pioneers, and entrepreneurs, who are all dedicated...

Havas Lynx

Generation Now: the impact of the millennial HCP on our world

Millennials are criticised as narcissistic, entitled and technology-obsessed, but our new campaign shows millennial healthcare professionals – mHCPs – in a different light. They have certainly grown up in a...

Havas Lynx

- PMLiVE

Keytruda is first FDA-approved drug for molecular indication

Indicates a significant development in the shift towards personalised medicine

Using service design to improve patients’ quality of life

Customer Experience Consultant Eimear Power talks through the process of developing Orello, a service for metastatic prostate cancer patients and their loved ones, in collaboration with Janssen.

Blue Latitude Health

National Institute for Health and Care Excellence NICE logo

NICE knocks-back Shire’s pancreatic cancer drug Onivyde

Final guidance rules it's not a cost-effective use of NHS resources

- PMLiVE

Havas brings consumer and professional health within one division

Havas Health & You will include agencies such as Health4Brands and Havas Lynx

- PMLiVE

Caring for prostate cancer patients

Although not without its challenges, the appropriate care and support available to patients with prostate cancer is gradually evolving. It’s important not to overlook the all too often ‘unsung heroes’...

Blue Latitude Health

Teva launches online cancer portal My Day

Follows social listening project on gender differences in cancer discussions

- PMLiVE

Novartis’ Zykadia nears first-line lung cancer label

Hopes to boost slow second-line sales to compete directly with Pfizer’s Xalkori and Roche’s Alecensa 

- PMLiVE

Argos hit as kidney cancer immunotherapy fails phase III trial

Study discontinued as data shows renal cell carcinoma vaccine unlikely to meet targets

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links